Study explores potential of HDACs to treat autoimmune diseases

10/7/2007 | Yahoo!

A new class of cancer drugs known as histone deacetylases inhibitors, or HDACs, may also treat autoimmune diseases such as rheumatoid arthritis and Crohn's disease, scientists report. In testing Merck's skin cancer treatment Zolinza, the researchers found that the drug enhanced the production of cells that regulate the immune system in mice, preventing inflammatory bowel disease and the rejection of heart transplants.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX